Elekta AB stock (SE0000163628): Included in OMX Stockholm ESG Index
Published on 05/13/2026 at 21:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elekta AB, a leading provider of precision radiation medicine solutions, is featured in the OMX Stockholm Benchmark ESG Responsible Gross Index weighting updated on May 13, 2026. The index, which tracks ESG-compliant companies, lists Elekta AB ser. B (EKTA B) at position 33, signaling strong environmental, social, and governance credentials. This placement underscores Elekta's role in sustainable healthcare innovation for US investors tracking global medtech exposure.
As of: 13.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Elekta AB (publ)
- Sector/industry: Medical devices / Radiation therapy
- Headquarters/country: Stockholm, Sweden
- Core markets: North America, Europe, Asia
- Key revenue drivers: Oncology systems, software, service
- Home exchange/listing venue: Nasdaq Stockholm (EKTA B)
- Trading currency: SEK
Elekta AB: core business model
Elekta AB develops and sells clinical solutions for treating cancer and brain disorders using radiation therapy and radiosurgery. Its portfolio includes linear accelerators like Versa HD and Leksell Gamma Knife, alongside software for treatment planning and oncology information systems. The company operates globally, with significant US market presence through installations in major cancer centers, according to Elekta.com as of 05/13/2026.
Revenue stems primarily from equipment sales, upgrades, and long-term service contracts. Elekta emphasizes precision medicine to minimize side effects, aligning with rising demand for non-invasive cancer treatments. For US investors, Elekta offers exposure to the expanding $10B+ US radiation oncology market.
Main revenue and product drivers for Elekta AB
Oncology systems account for the bulk of revenue, driven by products like Elekta Unity (MRI-guided radiotherapy) and Harmony linear accelerators. Service and software segments provide recurring income, with digital solutions like MOSAIQ OIS supporting over 4,000 cancer centers worldwide. North America contributes around 40% of sales, per company reports, making it relevant for US portfolios amid aging demographics boosting cancer care needs.
Recent index inclusion in OMXSBESGGI reflects Elekta's ESG integration, including sustainable manufacturing and diversity initiatives, as detailed in the Nasdaq OMX index weighting as of 05/13/2026.
Official source
For first-hand information on Elekta AB, visit the company’s official website.
Go to the official websiteIndustry trends and competitive position
The radiation therapy market is projected to grow at 6-7% CAGR through 2030, fueled by minimally invasive procedures and AI integration. Elekta competes with Varian Medical Systems (acquired by Siemens Healthineers) and Accuray, differentiating via MRI-Linac tech and brachytherapy offerings. Its ESG index status enhances appeal to sustainable funds, per IndexBox market overview.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Why Elekta AB matters for US investors
With heavy US revenue reliance and listings in major indices, Elekta provides diversified medtech exposure without direct Nasdaq listing. Its tech supports key US providers like MD Anderson, tying into the $200B+ US oncology spend. ESG weighting adds stability for long-term holders amid tariff concerns on EU medtech.
Conclusion
Elekta AB's inclusion in the OMX Stockholm ESG index highlights its sustainable positioning in radiation oncology. Ongoing innovation in precision therapy supports revenue growth potential, while global reach benefits US investors seeking international healthcare plays. Market dynamics and competition remain key factors to monitor.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
